21 04 2016
Aeglea BioTherapeutics, Inc.'s $54.8 million Initial Public OfferingDavis Polk advised the joint book-running managers and representatives of the several underwriters on the $54.8 million initial public offering by Aeglea BioTherapeutics, Inc. Aeglea’s common stock is listed on the NASDAQ Global Market under the symbol “AGLE.”
UBS Investment Bank, BMO Capital Markets, Wells Fargo Securities, Needham & Company acted as joint book-running managers.
Based in Austin, Texas, Aeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. The company, led by David G. Lowe, Charles N. York, Ann M. Lowe, Scott W. Rowlinson and Henry L. Hebel, was founded in 2013.
The Davis Polk corporate team included partner Bruce K. Dallas (Picture), counsel Jeffrey Gould and associate Keerthika Melissa Subramanian. The tax team included partner Rachel D. Kleinberg and associate Alexander Wu. The intellectual property and technology team included associates Michelle Gross and Jason J. Bang. Counsel Marcie A. Goldstein provided FINRA advice.
Involved fees earner: Bruce Dallas - Davis Polk & Wardwell; Jeffrey Gould - Davis Polk & Wardwell; Keerthika Melissa Subramanian - Davis Polk & Wardwell; Rachel Kleinberg - Davis Polk & Wardwell; Alexander Wu - Davis Polk & Wardwell; Michelle Gross - Davis Polk & Wardwell; Jason Bang - Davis Polk & Wardwell; Marcie Goldstein - Davis Polk & Wardwell;
29/03/2018
On March 23rd 2018, the world’s leading corporate stars reunited for a special
14/12/2017
On December 14th, 2017, the world’s leading corporate stars reunited for a spec
23/10/2017
On October 20th, 2017, the world’s leading corporate stars reunited for a speci
21/03/2017
Hong Kong has become a city of bright expansion, culture, and futuristic innovation. Fr
17/11/2016
Fintech, it’s described as the disruption in financial services pushed by consume